Home » Stocks » Liminal BioSciences

Liminal BioSciences Inc. (LMNL)

Stock Price: $5.73 USD 0.02 (0.35%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $5.87 +0.14 (2.44%) Oct 26, 7:58 PM

Stock Price Chart

Key Info

Market Cap 133.58M
Revenue (ttm) 3.74M
Net Income (ttm) -207.80M
Shares Out 23.31M
EPS (ttm) -9.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $5.73
Previous Close $5.71
Change ($) 0.02
Change (%) 0.35%
Day's Open 5.67
Day's Range 5.33 - 5.86
Day's Volume 582,567
52-Week Range 5.33 - 31.45

More Stats

Market Cap 133.58M
Enterprise Value 122.73M
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.31M
Float 6.79M
EPS (basic) n/a
EPS (diluted) -9.78
FCF / Share -4.94
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 15,016
Short Ratio 0.40
Short % of Float 0.22%
Beta 2.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 35.68
PB Ratio 3.34
Revenue 3.74M
Operating Income -99.71M
Net Income -207.80M
Free Cash Flow -79.26M
Net Cash 10.85M
Net Cash / Share 0.47
Gross Margin 43.66%
Operating Margin -2,663.58%
Profit Margin -4,237.30%
FCF Margin -2,117.33%
ROA -42.40%
ROE -138.63%
ROIC -141.90%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$10.09*
Low
10.1
Current: $5.73
High
10.1
Target: 10.09
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions CAD.

Financial Overview

Year201920182017
Revenue4.9024.6322.31
Revenue Growth-80.09%10.4%-
Gross Profit2.14-1.0718.62
Operating Income-131-265-125
Net Income-208-280-130
Shares Outstanding16.060.830.80
Earnings Per Share-12.81-235.95-137.85
Operating Cash Flow-99.39-82.45-123
Capital Expenditures-4.44-5.13-10.08
Free Cash Flow-104-87.58-133
Cash & Equivalents61.297.3938.87
Total Debt47.0712849.12
Net Cash / Debt14.21-120-10.25
Assets165103265
Liabilities70.16166106
Book Value102-56.60132
Numbers in millions CAD, except per-share numbers.

Company Profile

Company Details

Full Name Liminal BioSciences Inc.
Country Canada
Employees 300
CEO Kenneth Harry Galbraith

Stock Information

Ticker Symbol LMNL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LMNL

Description

Liminal BioSciences, a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.